DK0446570T3 - Gabapentin og dets derivater til behandling af neurodegenerative sygdomme - Google Patents

Gabapentin og dets derivater til behandling af neurodegenerative sygdomme

Info

Publication number
DK0446570T3
DK0446570T3 DK91100109.7T DK91100109T DK0446570T3 DK 0446570 T3 DK0446570 T3 DK 0446570T3 DK 91100109 T DK91100109 T DK 91100109T DK 0446570 T3 DK0446570 T3 DK 0446570T3
Authority
DK
Denmark
Prior art keywords
gabapentin
derivatives
treatment
neurodegenerative diseases
huntington
Prior art date
Application number
DK91100109.7T
Other languages
Danish (da)
English (en)
Inventor
Geoffrey Neil Woodruff
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27039510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0446570(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK0446570T3 publication Critical patent/DK0446570T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK91100109.7T 1990-01-02 1991-01-02 Gabapentin og dets derivater til behandling af neurodegenerative sygdomme DK0446570T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45991290A 1990-01-02 1990-01-02
US07/615,151 US5084479A (en) 1990-01-02 1990-11-23 Novel methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
DK0446570T3 true DK0446570T3 (da) 1995-11-27

Family

ID=27039510

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91100109.7T DK0446570T3 (da) 1990-01-02 1991-01-02 Gabapentin og dets derivater til behandling af neurodegenerative sygdomme

Country Status (7)

Country Link
US (1) US5084479A (de)
EP (1) EP0446570B1 (de)
JP (1) JP2903434B2 (de)
AT (1) ATE125701T1 (de)
DE (1) DE69111642T2 (de)
DK (1) DK0446570T3 (de)
HK (1) HK1005166A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
UA49011C2 (uk) * 1996-03-14 2002-09-16 Варнер-Ламберт Компані Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
KR100630506B1 (ko) * 1997-06-30 2006-09-29 메르츠 파마 게엠베하 운트 코. 카가아 Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
US6194459B1 (en) 1997-08-19 2001-02-27 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
HUP0004310A3 (en) * 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
DE19751062A1 (de) 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
CA2327285C (en) * 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US6294198B1 (en) * 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
IL153398A0 (en) 2000-06-16 2003-07-06 Teva Pharma Stable gabapentin containing more than 20 ppm of chlorine ion
PL359872A1 (en) * 2000-06-26 2004-09-06 Warner-Lambert Company Gabapentin analogues for sleep disorders
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
CA2449729C (en) * 2001-06-11 2009-11-03 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
EP1471909A4 (de) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003089403A1 (en) * 2002-04-16 2003-10-30 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
NZ579515A (en) 2003-09-17 2011-09-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
SG147437A1 (en) 2003-10-14 2008-11-28 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
MX2007005306A (es) * 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2575798B1 (de) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosierungszubereitung von gaba analoga
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US20220296548A1 (en) * 2019-10-25 2022-09-22 Kyoto University Preventative or therapeutic agent for tauopathy
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
JPH04210915A (ja) 1992-08-03
ATE125701T1 (de) 1995-08-15
DE69111642T2 (de) 1996-01-25
HK1005166A1 (en) 1998-12-24
EP0446570A2 (de) 1991-09-18
EP0446570B1 (de) 1995-08-02
EP0446570A3 (en) 1992-04-01
US5084479A (en) 1992-01-28
JP2903434B2 (ja) 1999-06-07
DE69111642D1 (de) 1995-09-07

Similar Documents

Publication Publication Date Title
DK0446570T3 (da) Gabapentin og dets derivater til behandling af neurodegenerative sygdomme
DK0414275T3 (da) Fremgangsmåde til fremtilling af cycliske aminosyrederivater samt mellemprodukter
DK0831799T3 (da) Forbindelser, der er aktive ved et nyt sted på receptor-stimulerede calsiumkanaler, og som kan anvendes til behandling af neurologiske sygdomme
ATE221885T1 (de) Substituierte sulfonylphenylheterocyclen als cyclooxygenase-2 und 5- lipoxygenase inhibitoren
SE8704204L (sv) Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma
NO20083956L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DE60124080D1 (de) Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
BR9812837A (pt) Processo para fazer um composto, e, composto
ATE480235T1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
ES2116298T3 (es) Nuevo metodo de tratamiento de la depresion.
DE69014707D1 (de) Verfahren zur Herstellung von CMOS-Feldeffekt-Transistoren.
BR9808923A (pt) Composto, e, processo para fazer o mesmo
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DK671187D0 (da) Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme
FI97884B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 3,4-dihydroksi-2,5-dihydrofuranonien valmistamiseksi
FI102537B (fi) Dehalogenointimenetelmä 3-aroyyli-2-oksindoli-1-karboksiamidien valmis tamiseksi
ATE123488T1 (de) Verfahren zur herstellung von benzolsulfonamiden.
ATE323690T1 (de) Bicyclische(3.1.0)hexane und verwandte verbindungen
ATE137973T1 (de) Phospholipide zur behandlung der multiplen sklerose
MX9704739A (es) Monomeros de 3,3-(disustituido)ciclohexan-1-ona y compuestos relacionados.